Triple
T13942272
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | SARS-CoV-2 |
E335284
|
entity |
| Predicate | preventedBy |
P957
|
FINISHED |
| Object | COVID-19 vaccine |
E123479
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: COVID-19 vaccine | Statement: [SARS-CoV-2, preventedBy, COVID-19 vaccine]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: COVID-19 vaccine Context triple: [SARS-CoV-2, preventedBy, COVID-19 vaccine]
-
A.
COVID-19 vaccines
chosen
COVID-19 vaccines are immunizations developed to protect against the SARS-CoV-2 virus, significantly reducing the risk of severe illness, hospitalization, and death from COVID-19.
-
B.
Vaxzevria COVID-19 vaccine
Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
-
C.
Janssen COVID-19 Vaccine
The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
-
D.
mRNA vaccine
An mRNA vaccine is a type of vaccine that uses a small piece of messenger RNA to instruct cells to produce a viral protein, triggering an immune response without using a live virus.
-
E.
BNT162b2
BNT162b2 is an mRNA-based COVID-19 vaccine, co-developed by BioNTech and Pfizer, that became one of the first widely authorized vaccines against SARS-CoV-2.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d81c6081b88190b53e317c3370c8fe |
completed | April 9, 2026, 9:38 p.m. |
| NER | Named-entity recognition | batch_69de2e0f6f3c8190a64058b732b0ac52 |
completed | April 14, 2026, 12:07 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69f7ce8bbd8c819084703298ed6d9c87 |
completed | May 3, 2026, 10:39 p.m. |
Created at: April 9, 2026, 10:17 p.m.